Evidence map›Paper›PMID 27026366›Full record

ArticleJournal of the American Society of Nephrology : JASN2016

TWEAK-Fn14 Signaling Activates Myofibroblasts to Drive Progression of Fibrotic Kidney Disease.

Ivan G Gomez, Allie M Roach, Naoki Nakagawa, Aldo Amatucci, Bryce G Johnson, Kadeshia Dunn, Mark C Kelly, Gamze Karaca, Timothy S Zheng, Suzanne Szak and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Ivan G GomezResearch & Development, Biogen, Cambridge, Massachusetts.
Allie M RoachResearch & Development, Biogen, Cambridge, Massachusetts.
Naoki NakagawaDivision of Nephrology, Departments of Medicine & Pathology, and Institute of Stem Cell & Regenerative Medicine, University of Washington, Seattle, Washington; and.
Aldo AmatucciResearch & Development, Biogen, Cambridge, Massachusetts.
Bryce G JohnsonResearch & Development, Biogen, Cambridge, Massachusetts.
Kadeshia DunnMedway School of Pharmacy, University of Kent, Chatham, Kent, United Kingdom.
Mark C KellyMedway School of Pharmacy, University of Kent, Chatham, Kent, United Kingdom.
Gamze KaracaResearch & Development, Biogen, Cambridge, Massachusetts.
Timothy S ZhengResearch & Development, Biogen, Cambridge, Massachusetts.
Suzanne SzakResearch & Development, Biogen, Cambridge, Massachusetts.
Claire M Peppiatt-WildmanMedway School of Pharmacy, University of Kent, Chatham, Kent, United Kingdom.
Linda C BurklyResearch & Development, Biogen, Cambridge, Massachusetts; jeremy.duffield@biogen.com linda.burkly@biogen.com.
Jeremy S DuffieldResearch & Development, Biogen, Cambridge, Massachusetts; jeremy.duffield@biogen.com linda.burkly@biogen.com.
Biogen (United States) · USUniversity of Washington · USMedway School of Pharmacy · GBUniversity of Kent · GB

Funding

Using iPSCs to model patient outcomes in nephrotic syndromeUH3TR000504 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2014 to 2016
$6.1M
Pericyte-endothelial cross talk in vascular stability after kidney injuryR01DK093493 · NIDDK · UNIVERSITY OF WASHINGTON · PI SHANKLAND, STUART JAMES · 2012 to 2016
$2.5M
A Tissue Engineered Human Kidney Microphysiological SystemUH2TR000504 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2012 to 2013
$2.1M
PDGFR-beta+ stromal cells as critical regulators of immune response to tissue injuryR01HL122895 · NHLBI · UNIVERSITY OF WASHINGTON · PI ALTEMEIER, WILLIAM A · 2015 to 2018
$1.7M
Kidney pericytes in vascular regeneration after injuryRC1DK087389 · NIDDK · UNIVERSITY OF WASHINGTON · PI DUFFIELD, JEREMY S · 2009 to 2010
$989k
Kidney Progenitor Cells in DiseaseR24DK094768 · NIDDK · UNIVERSITY OF WASHINGTON · PI GROSS, KENNETH W, PRUITT, STEVEN C · 2012 to 2012
$533k
NCATS NIH HHS UH2 TR000504NCATS NIH HHS UH3 TR000504NHLBI NIH HHS R01 HL122895NIDDK NIH HHS R01 DK093493NIDDK NIH HHS R24 DK094768NIDDK NIH HHS RC1 DK087389
6 · The paper itself

Abstract

The identification of the cellular origins of myofibroblasts has led to the discovery of novel pathways that potentially drive myofibroblast perpetuation in disease. Here, we further investigated the role of innate immune signaling pathways in this process. In mice, renal injury-induced activation of pericytes, which are myofibroblast precursors attached to endothelial cells, led to upregulated expression of TNF receptor superfamily member 12a, also known as fibroblast growth factor-inducible 14 (Fn14), by these cells. In live rat kidney slices, administration of the Fn14 ligand, TNF-related weak inducer of apoptosis (TWEAK), promoted pericyte-dependent vasoconstriction followed by pericyte detachment from capillaries. In vitro, administration of TWEAK activated and differentiated pericytes into cytokine-producing myofibroblasts, and further activated established myofibroblasts in a manner requiring canonical and noncanonical NF-κB signaling pathways. Deficiency of Fn14 protected mouse kidneys from fibrogenesis, inflammation, and associated vascular instability after in vivo injury, and was associated with loss of NF-κB signaling. In a genetic model of spontaneous CKD, therapeutic delivery of anti-TWEAK blocking antibodies attenuated disease progression, preserved organ function, and increased survival. These results identify the TWEAK-Fn14 signaling pathway as an important factor in myofibroblast perpetuation, fibrogenesis, and chronic disease progression.

Indexed as

Signal TransductionAnimalsCytokine TWEAKDisease ProgressionFibrosisKidneyKidney DiseasesMiceMyofibroblastsReceptors, Tumor Necrosis FactorTumor Necrosis FactorsTWEAK ReceptorCytokine TWEAKReceptors, Tumor Necrosis FactorTnfrsf12a protein, mouseTnfrsf12a protein, ratTnfsf12 protein, mouseTumor Necrosis FactorsTWEAK ReceptorAlport nephropathychronickidney diseasemyofibroblastpericytevascular biology

Identifiers

PMID27026366
PMCPMC5118488
OpenAlexW2315128454

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.